Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study

Soularue, Émilie; Cohen, Romain; Tournigand, Christophe; Zaanan, Aziz; Louvet, Christophe; Bachet, Jean‐Baptiste; Hentic, Olivia; Samalin, Emmanuelle; Chibaudel, Benoist; Gramont, Aimery de; André, Thierry

doi:10.1016/j.bulcan.2014.08.001

Cited by 49 publications

(57 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study of 34 patients with metastatic gastric or EGJ adenocarcinoma, the combination of trastuzumab with a modified FOLFOX regimen (mFOLFOX6) improved tolerability compared with the cisplatin plus fluorouracil regimen in previously untreated patients with HER2-positive tumors. 141 The ORR with this regimen was 41%, and median PFS and OS were 9.0 months and 17.3 months, respectively. The most frequent grade 3-4 toxicities were neutropenia (8.8%) and neuropathy (17.6%).…”

Section: Trastuzumabmentioning

confidence: 80%

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Ajani

D’Amico

Bentrem

et al. 2019

Journal of the National Comprehensive Cancer Network

752

705

View full text Add to dashboard Cite

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

show abstract

Section: Trastuzumabmentioning

confidence: 80%

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Ajani

D’Amico

Bentrem

et al. 2019

Journal of the National Comprehensive Cancer Network

752

705

View full text Add to dashboard Cite

show abstract

“…The HER2-blocking antibody trastuzumab has thus been combined with cisplatin and fluoropyrimidine to treat HER2-positive advanced gastric or GE junction adenocarcinoma; the ToGA trial showed that improvement in overall survival is particularly pronounced in patients with HER2 immunohistochemistry (IHC) 3 + or HER2 IHC 2 + and FISH-positive tumors [5,6]. Since that trial, trastuzumab has been shown effective and safe in combination with other 2-drug chemotherapy regimens such as XELOX, FOLFOX, and S1 plus cisplatin as first-line therapy [7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Median PFS was 9.8 months, and OS was 21 months with 63% of patients living at least one year after starting treatment. A recently published retrospective analysis from France yielded similar results with a PFS of 9.0 months and an OS of 17.3 months [ 66 ]. These outcomes compare favorably to data from ToGA.…”

Section: Aberrant Receptor Tyrosine Kinase Pathways With Therapeutic mentioning

confidence: 55%

Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.

Woo

Cohen

Grim

2015

Gastroenterol. Rep.

View full text Add to dashboard Cite

Gastroesophageal cancer is a significant global problem that frequently presents at an incurable stage and has very poor survival with standard chemotherapy approaches. This review will examine the epidemiology and molecular biology of gastroesophageal cancer and will focus on the key deregulated signaling pathways that have been targeted in the clinic. A comprehensive overview of clinical data highlighting successes and failures with targeted agents will be presented. Most notably, HER2-targeted therapy with the monoclonal antibody trastuzumab has proven beneficial in first-line therapy and has been incorporated into standard practice. Targeting the VEGF pathway has also proven beneficial, and the VEGFR-targeted monoclonal antibody ramucirumab is now approved for second-line therapy. In contrast to these positive results, agents targeting the EGFR and MET pathways have been evaluated extensively in gastroesophageal cancer but have repeatedly failed to show benefit. An increased understanding of the molecular predictors of response to targeted therapies is sorely needed. In the future, improved molecular pathology approaches should subdivide this heterogeneous disease entity to allow individualization of cancer therapy based on integrated and global identification of deregulated signaling pathways. Better patient selection, rational combinations of targeted therapies and incorporation of emerging immunotherapeutic approaches should further improve the treatment of this deadly disease.

show abstract

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study

Cited by 49 publications

References 40 publications

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.

Contact Info

Product

Resources

About